WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 510311
CAS#: 217645-70-0 (free base)
Description: BX-471, also known as ZK-811752, is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1). BX-471 exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. BX-471 was developed Berlex and its parent company, Schering AG. BX-471 is the lead in a series of non-peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular multiple sclerosis (MS). In March 2000, BX-471 was undergoing phase I trials for the potential treatment of autoimmune diseases.
MedKoo Cat#: 510311
Name: BX-471
CAS#: 217645-70-0 (free base)
Chemical Formula: C21H24ClFN4O3
Exact Mass: 434.1521
Molecular Weight: 434.89
Elemental Analysis: C, 58.00; H, 5.56; Cl, 8.15; F, 4.37; N, 12.88; O, 11.04
BX471, purity > 98%, is in stock. The same day shipping out after order is received.
Related CAS #: 217645-70-0 (Free base) 288262-96-4 (HCl)
Synonym: BX471; BX 471; BX-471; ZK811752; ZK 811752; ZK-811752.
IUPAC/Chemical Name: (R)-1-(5-chloro-2-(2-(4-(4-fluorobenzyl)-2-methylpiperazin-1-yl)-2-oxoethoxy)phenyl)urea
InChi Key: XQYASZNUFDVMFH-CQSZACIVSA-N
InChi Code: InChI=1S/C21H24ClFN4O3/c1-14-11-26(12-15-2-5-17(23)6-3-15)8-9-27(14)20(28)13-30-19-7-4-16(22)10-18(19)25-21(24)29/h2-7,10,14H,8-9,11-13H2,1H3,(H3,24,25,29)/t14-/m1/s1
SMILES Code: C[C@H]1N(C(COC2=CC=C(Cl)C=C2NC(N)=O)=O)CCN(CC3=CC=C(F)C=C3)C1
The following data is based on the product molecular weight 434.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Vandemeulebroecke M, Lembcke J, Wiesinger H, Sittner W, Lindemann S. Assessment of QT(c)-prolonging potential of BX471 in healthy volunteers. A 'thorough QT study' following ICH E14 using various QT(c) correction methods. Br J Clin Pharmacol. 2009 Sep;68(3):435-46. doi: 10.1111/j.1365-2125.2009.03460.x. PubMed PMID: 19740402; PubMed Central PMCID: PMC2766484.
2: He M, Horuk R, Bhatia M. Treatment with BX471, a nonpeptide CCR1 antagonist, protects mice against acute pancreatitis-associated lung injury by modulating neutrophil recruitment. Pancreas. 2007 Mar;34(2):233-41. PubMed PMID: 17312463.
3: He M, Horuk R, Moochhala SM, Bhatia M. Treatment with BX471, a CC chemokine receptor 1 antagonist, attenuates systemic inflammatory response during sepsis. Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1173-80. Epub 2007 Jan 18. Erratum in: Am J Physiol Gastrointest Liver Physiol. 2012 Jan;302(1):G194. PubMed PMID: 17234893.
4: Horuk R. BX471: a CCR1 antagonist with anti-inflammatory activity in man. Mini Rev Med Chem. 2005 Sep;5(9):791-804. Review. PubMed PMID: 16178722.